FDA Approves Pandemic Flu Vaccine From SEQIRUS/CSL Behring

Medscape  reports that the FDA has approved Audenz, “the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain.” According to Medscape, “Influenza A (H5N1) monovalent vaccine, adjuvanted...is for use in individuals aged 6 months and older.” The vaccine is “designed to be rapidly deployed to help protect the US population and can be stockpiled for first responders in the event of a pandemic.”

  

Healio also covers the story.